Loading
Loading…
Loading…
| # | Company | Status |
|---|---|---|
| 1 | Accepted-Technical MUMBAI MUMBAI MAHARASHTRA | Accepted-Technical ACCEPT |
| 2 | Accepted-Technical | Accepted-Technical ACCEPT |
| 3 | Accepted-Technical | Accepted-Technical ACCEPT |
| 4 | Accepted-Technical 0 DAWA MARKET JAISTAMBHA CHOUK DAWA BAZAR AMRAVATI MAHARASHTRA 444601 | AMRAVATI | MAHARASHTRA | 444601 | Accepted-Technical ACCEPT |
| 5 | Accepted-Technical | Accepted-Technical ACCEPT |
Tender Value
Refer Docs
EMD Value
₹50,000
Closing Date
11 Jun 2026, 5:00 pmClosed
MS RRSH
MS RRSH Amravati
Medicine for cancer
2026_DHS_1306229_1
E-Tender E-06/RRSH/MEDICINECANCER/26-27
Open Tender
Medicines
Item Rate
RRSH AMRAVATI
Please refer Tender documents.
2 documents required · 2 mandatory
₹3,000
₹50,000
Yes
RRSH Amravati
15 Jun 2026
2 Jun 2026
13 Jun 2026
2 Jun 2026
11 Jun 2026
2 Jun 2026
5 Jun 2026
| Sl No | Description | Qty | Unit | Est. Rate | Est. Amount |
|---|---|---|---|---|---|
| 1MEDICINE OF CANCER | |||||
| 1.01 | Cap Alectinib 150mg | - | Nos | 1 | - |
| 1.02 | Cap Aprepitant 125mg80 MG | - | Nos | 1 | - |
| 1.03 | Cap CERITINIB 150 MG | - | Nos | 1 | - |
| 1.04 | Cap CRIZOTINIB 200 MG | - | Nos | 1 | - |
| 1.05 | Cap CRIZOTINIB 250 MG | - | Nos | 1 | - |
| 1.06 | Cap ENZALUTAMIDE 160MG | - | Nos | 1 | - |
| 1.07 | Cap ENZALUTAMIDE 40 MG | - | Nos | 1 | - |
| 1.08 | Cap ETOPOSIDE 50 MG | - | Nos | 1 | - |
| 1.09 | Cap EVEROLIMUS 10 MG | - | Nos | 1 | - |
stage.html
html • 0.03 MB
tech_bid_open.pdf
tech_eval.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Tendernotice_1.pdf
PDF • 9.16 MB
BOQ_2241909.xls
BOQ • 0.35 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .